Evidence map›Paper›PMID 42771716›Full record

Trial reportJournal of the International AIDS Society2026

Understanding Adolescent Anti-Retroviral Therapy Use in the BREATHER-Plus Trial: Qualitative Findings From South Africa and Uganda.

Londiwe Shandu, Stella Namukwaya, Tamlyn Carmin Seunanden, Nothando Ngwenya, Moherndran Archary, Cissy Kityo, Deborah Ford, Sarah L Pett, Adeodata R Kekitiinwa, Sarah Bernays and 2 more

Abstract readRandomized Controlled TrialEquivalence Trial
In one paragraph

Trial report in Journal of the International AIDS Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Londiwe Shandu *Africa Health Research Institute, KwaZulu-Natal, South Africa.ORCID https://orcid.org/0009-0007-7787-1401
Stella Namukwaya *MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.ORCID https://orcid.org/0009-0003-9217-3418
Tamlyn Carmin SeunandenAfrica Health Research Institute, KwaZulu-Natal, South Africa.ORCID https://orcid.org/0000-0002-8803-3696
Nothando NgwenyaAfrica Health Research Institute, KwaZulu-Natal, South Africa.ORCID https://orcid.org/0000-0002-5630-6389
Moherndran ArcharyMRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.ORCID https://orcid.org/0000-0003-3082-9234
Cissy KityoJoint Clinical Research Centre, Kampala, Uganda.ORCID https://orcid.org/0000-0002-9286-7052
Deborah FordMedical Research Council Clinical Trials Unit at University College London (UCL), London, UK.ORCID https://orcid.org/0000-0003-1713-6302
Sarah L PettMedical Research Council Clinical Trials Unit at University College London (UCL), London, UK.ORCID https://orcid.org/0000-0002-4851-4727
Adeodata R KekitiinwaBaylor College of Medicine Children's Foundation, Kampala, Uganda.ORCID https://orcid.org/0000-0001-8240-1796
Sarah BernaysSydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-7628-8408
Janet SeeleyAfrica Health Research Institute, KwaZulu-Natal, South Africa.ORCID https://orcid.org/0000-0002-0583-5272
BREATHER‐Plus trial team

Funding

European and Developing Countries Trial Partnership 2 programme RIA2017MC-2005Medical Research Council MC_UU_00004/03andMC_UU_00004/04Wellcome TrustWellcome Trust 227167/A/23/Zand224310/Z/21/Z
6 · The paper itself

Abstract

introductionThe BREATHER-Plus trial was an open-label, randomized non-inferiority trial comparing weekends off antiretroviral therapy (ART) (short cycle therapy [SCT]) with daily oral ART (continuous therapy [CT]) for adolescents aged 12-19 years. We present findings from the qualitative sub-study on the factors influencing trial participants' decisions to take/not take ART in accordance with their randomized arm.

methodsQualitative data collection was conducted in South Africa and Uganda from December 2022 to July 2024 using in-depth interviews (IDIs) and focus group discussions (FGDs). We purposively recruited 29 trial participants (14 SCT/15 CT arm) to take part in IDIs in South Africa. From the trial sites in both countries, 47 trial participants, 17 non-trial participants, 15 caregivers and 16 healthcare providers took part in FGDs. Data collection with trial participants focused on adherence to SCT compared to daily ART; the acceptability of SCT and the experience of taking part in the trial. All FGDs explored the feasibility of SCT and preferences for alternative approaches to accessing therapy. Data were analysed thematically.

resultsBoth IDI and FGD data showed that the opportunity to have weekends off from treatment was welcomed by participants, caregivers and healthcare providers. However, the understanding of "2 days off" treatment was interpreted flexibly by some participants. Trial participants in both arms described their fluctuating adherence practices both prior to and during the trial. The introduction of SCT as a possibility through the trial prompted some to talk about previously concealed missed doses. Participants reported that they only mentioned missed doses in the clinic if they had a raised viral load result or had returned to the clinic with too many pills. Many participants relied on their viral load result to confirm that non-adherent behaviour was not problematic.

conclusionsOur findings offer insights into the factors that shape ART adherence among adolescents living with HIV. Adherence is not a static behaviour but a socially embedded and relational practice, shaped by adolescents' interpretations of treatment, interpersonal relationships and the structure of care environments. Regimen modification alone does not resolve the broader social and emotional challenges adolescents face.

Indexed as

Anti-HIV AgentsAnti-Retroviral AgentsHIV InfectionsMedication AdherenceAdolescentChildFemaleFocus GroupsHumansMaleQualitative ResearchSouth AfricaUgandaYoung AdultAnti-HIV AgentsAnti-Retroviral Agentsadolescentsantiretroviral therapyclinical trialsHIVSouth AfricaUgandayoung people

Identifiers

PMID42771716
PMCPMC13596911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.